Investments
187Portfolio Exits
52Funds
8About River Cities Capital Fund
River Cities Capital Funds is one of the most active and experienced growth equity funds in healthcare and information technology (IT). With nearly $500 million under management and more than 100 investments made, River Cities has established itself as a preferred partner among the entrepreneurial and private equity communities. River Cities seeks to invest in high-growth IT and healthcare companies that have a market-validated proposition. Its performance is driven by our ability to access, evaluate, consummate and build companies that can lead the transformation of specific market segments by pursuing large, established markets with disruptive technologies or service offerings that are significantly "better, faster, cheaper" than incumbent solutions.
River Cities Capital Fund Headquarter Location
221 East Fourth Street Suite 2400
Cincinnati, Ohio, 45202,
United States
513-621-9700
Expert Collections containing River Cities Capital Fund
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find River Cities Capital Fund in 1 Expert Collection, including Agriculture Technology (Agtech).
Agriculture Technology (Agtech)
24 items
Companies that are using technology to make farms more efficient
Latest River Cities Capital Fund News
Apr 16, 2019
(Bardy DIagnostics Photo) Seattle-based medical device company Bardy Diagnostics today announced a $35.5 million funding round led by River Cities Capital Fund. The company makes the Carnation Ambulatory Monitor (CAM), which is a small, lightweight heart monitor that can detect arrhythmia. Bardy said the money would be used to grow its platform by expanding its sales force and monitoring services, as well as to invest in augmented intelligence and visualization technologies. The series B funding round drew new investors HealthQuest Capital, Aperture Venture Partners, Aphelion Capital, Lumira Ventures and Rex Health Ventures. Bardy’s device, which is used to monitor more than 40,000 patients, competes with other non-invasive cardiac monitors such as the iRhythm Zio. The CAM is meant to be worn comfortably for a week, designed to lead to higher rates of patient compliance. Bardy claims that its device captures clearer and more accurate heart rhythms than competing ECG monitors. The Carnation Ambulatory Monitor, or CAM for short, is designed to be worn comfortably for approximately a week, with the goal of improving patient compliance. (Bardy Diagnostics Photo) “For nearly 60 years, standard ECG engineering practices have over-processed the heart’s electrical message to make machines’ ‘lives’ easier at the expense of losing details in the ECG,” CEO Dr. Gust Bardy said in a statement . “In essence, such legacy engineering doesn’t listen to what the heart is trying to tell us but rather tells the heart what we are willing to hear.” Dr. Bardy is a longtime cardiac electrophysiologist who also serves as a clinical professor of medicine, cardiology, at the University of Washington and is the director of the Seattle Institute for Cardiac Research. Dr. Bardy sold his previous company, Cameron Health, to Boston Scientific in 2012. Rik Vandevenne, managing director of River Cities Capital Funds, and Garheng Kong, managing director of HealthQuest Capital, were named to Bardy’s board of directors as a result of the new funding. The company recently expanded its reach to Canada through an alliance with JNC Medical, a medical technologies distributor based in Ottawa, Ontario. Seattle-based journalist James Thorne is an NYU business and economics journalism grad who has written for publications including Reuters, CNBC, and Financial Planning. Follow him on Twitter @jamescthorne .
River Cities Capital Fund Investments
187 Investments
River Cities Capital Fund has made 187 investments. Their latest investment was in Q'Apel Medical as part of their Unattributed VC on April 4, 2022.
River Cities Capital Fund Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
4/4/2022 | Unattributed VC | Q'Apel Medical | $29.9M | No | 2 | |
10/6/2021 | Series D | Catalyst Orthoscience | $12.3M | No | 7 | |
8/31/2021 | Series D | SPR Therapeutics | $37M | Yes | 4 | |
6/7/2021 | Series C | |||||
6/1/2021 | Series B |
Date | 4/4/2022 | 10/6/2021 | 8/31/2021 | 6/7/2021 | 6/1/2021 |
---|---|---|---|---|---|
Round | Unattributed VC | Series D | Series D | Series C | Series B |
Company | Q'Apel Medical | Catalyst Orthoscience | SPR Therapeutics | ||
Amount | $29.9M | $12.3M | $37M | ||
New? | No | No | Yes | ||
Co-Investors | |||||
Sources | 2 | 7 | 4 |
River Cities Capital Fund Portfolio Exits
52 Portfolio Exits
River Cities Capital Fund has 52 portfolio exits. Their latest portfolio exit was Building Engines on October 21, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
10/21/2021 | Acquired | 3 | |||
10/14/2021 | Acquired | 3 | |||
8/6/2021 | Acquired | 15 | |||
Date | 10/21/2021 | 10/14/2021 | 8/6/2021 | ||
---|---|---|---|---|---|
Exit | Acquired | Acquired | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 3 | 3 | 15 |
River Cities Capital Fund Acquisitions
3 Acquisitions
River Cities Capital Fund acquired 3 companies. Their latest acquisition was Carolina Partners in Mental Healthcare on September 27, 2018.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
9/27/2018 | Acq - Fin | 2 | ||||
4/15/2008 | Private Equity | |||||
4/4/2008 | Private Equity |
Date | 9/27/2018 | 4/15/2008 | 4/4/2008 |
---|---|---|---|
Investment Stage | Private Equity | Private Equity | |
Companies | |||
Valuation | |||
Total Funding | |||
Note | Acq - Fin | ||
Sources | 2 |
River Cities Capital Fund Fund History
8 Fund Histories
River Cities Capital Fund has 8 funds, including River Cities Capital Fund VII.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
1/18/2022 | River Cities Capital Fund VII | $161M | 1 | ||
8/2/2019 | River Cities Capital Fund VI | ||||
5/20/2014 | River Cities Capital Fund V | ||||
12/19/2008 | River Cities Capital Fund II | ||||
3/31/2008 | River Cities Capital Fund IV |
Closing Date | 1/18/2022 | 8/2/2019 | 5/20/2014 | 12/19/2008 | 3/31/2008 |
---|---|---|---|---|---|
Fund | River Cities Capital Fund VII | River Cities Capital Fund VI | River Cities Capital Fund V | River Cities Capital Fund II | River Cities Capital Fund IV |
Fund Type | |||||
Status | |||||
Amount | $161M | ||||
Sources | 1 |
River Cities Capital Fund Team
7 Team Members
River Cities Capital Fund has 7 team members, including current Managing Director, Daniel T. Fleming.
Name | Work History | Title | Status |
---|---|---|---|
Daniel T. Fleming | Managing Director | Current | |
Rob Heiman | Managing Director | Current | |
Robert A. Heimann | The Brandery | Managing Director | Current |
R. Glen Mayfield | Managing Director | Current | |
Edwin T. Robinson | Managing Director | Current |
Name | Daniel T. Fleming | Rob Heiman | Robert A. Heimann | R. Glen Mayfield | Edwin T. Robinson |
---|---|---|---|---|---|
Work History | The Brandery | ||||
Title | Managing Director | Managing Director | Managing Director | Managing Director | Managing Director |
Status | Current | Current | Current | Current | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.